Aleniglipron

Aleniglipron
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 3-[(1S,2S)-1-[2-[[(4S)-3-[3-[4-(Diethylphosphinyl)-3-(methylamino)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazol-5(2H)-one;
CAS Number	2685823-26-9;
PubChem CID	164809721;
DrugBank	DB18551;
Chemical and physical data
Formula	C49H55FN9O6P
Molar mass	916.008 g·mol−1
	InChI InChI=1S/C49H55FN9O6P/c1-8-66(63,9-2)41-13-11-35(26-38(41)51-7)56-18-19-57(48(56)62)44-42-31(6)55(17-14-37(42)53-59(44)36-22-28(3)43(50)29(4)23-36)45(60)40-25-34-24-33(32-15-20-64-21-16-32)10-12-39(34)58(40)49(27-30(49)5)46-52-47(61)65-54-46/h10-13,18-19,22-26,30-32,51H,8-9,14-17,20-21,27H2,1-7H3,(H,52,54,61)/t30-,31-,49-/m0/s1; Key:CPOJUYUGONJVPZ-WIXASUBBSA-N;

Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics.^[1] It is delivered orally and is in a Phase II trial as of 2023.^[2]^[3]^[4] In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.^[5]

References

^ Mao, Ting; Meng, Qinghua; Zhang, Haizhen; Zhang, Jinqiang J.; Shi, Songting; Guan, Zhibo; Jiang, Xinglong; Zhang, Fang; Lei, Hui; Lin, Xichen (20 June 2023). "760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist". Diabetes. 72 (Supplement_1). doi:10.2337/db23-760-P. S2CID 259430363.
^ "Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity". BioSpace. 25 May 2023. Retrieved 4 November 2023.
^ "Structure announces positive results from oral GLP-1 receptor agonist gsbr-1290". Bariatric News. 2 October 2023. Retrieved 4 November 2023.
^ Satija, Bhanvi (29 September 2023). "Structure Therapeutics surges as early data from obesity pill tops expectations". Reuters. Retrieved 4 November 2023.
^ "Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290". BioSpace. 2024-06-03. Retrieved 2024-10-24.

[1] Mao, Ting; Meng, Qinghua; Zhang, Haizhen; Zhang, Jinqiang J.; Shi, Songting; Guan, Zhibo; Jiang, Xinglong; Zhang, Fang; Lei, Hui; Lin, Xichen (20 June 2023). "760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist". Diabetes. 72 (Supplement_1). doi:10.2337/db23-760-P. S2CID 259430363.

[2] "Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity". BioSpace. 25 May 2023. Retrieved 4 November 2023.

[3] "Structure announces positive results from oral GLP-1 receptor agonist gsbr-1290". Bariatric News. 2 October 2023. Retrieved 4 November 2023.

[4] Satija, Bhanvi (29 September 2023). "Structure Therapeutics surges as early data from obesity pill tops expectations". Reuters. Retrieved 4 November 2023.

[5] "Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290". BioSpace. 2024-06-03. Retrieved 2024-10-24.

[1]

[2]

[3]

[4]

[5]